1naresh2naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) [bdce45a9-4286-4c99-bc2a-0856f0fe7d2b] => Array ( [runtime-id] => bdce45a9-4286-4c99-bc2a-0856f0fe7d2b [type] => toll-free-key [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [0b8cc3d2-2a61-4dc5-b26c-b3a9ba7b22d5] => Array ( [runtime-id] => 0b8cc3d2-2a61-4dc5-b26c-b3a9ba7b22d5 [type] => toll-free-key ) ) [credentials] => Array ( [method] => toll-free-key [value] => tf_ipsecsha;2a99ed02782a62da9029f1897f5d751b5d0f6fd5 ) ) ) 1naresh2nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) [bdce45a9-4286-4c99-bc2a-0856f0fe7d2b] => Array ( [runtime-id] => bdce45a9-4286-4c99-bc2a-0856f0fe7d2b [type] => toll-free-key [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [0b8cc3d2-2a61-4dc5-b26c-b3a9ba7b22d5] => Array ( [runtime-id] => 0b8cc3d2-2a61-4dc5-b26c-b3a9ba7b22d5 [type] => toll-free-key ) ) [credentials] => Array ( [method] => toll-free-key [value] => tf_ipsecsha;2a99ed02782a62da9029f1897f5d751b5d0f6fd5 ) ) )Table 1:Demographic and clinical data for control and patient groupsa
Control PD MSA-P PSP P Value No. of subjects 36 35 16 19 Female/male 13:23 12:23 8:8 4:15 .356b Age (yr) 70.0 ± 7.5 70.3 ± 7.9 68.0 ± 7.5 74.9 ± 8.7 .057c Disease duration (yr) – 3.4 ± 3.6 3.9 ± 3.3 3.2 ± 2.8 .812c MoCA 25 ± 2.3 22.8 ± 4.5 23.9 ± 2.7 20.1 ± 4.9 .002,d .120e UPDRS III 4.6 ± 3.6 36.6 ± 27.3 51.5 ± 20.0 46.6 ± 23.4 <.0001,d .145e
↵a Data are sums or mean ± SD.
↵b Group difference in sex was compared among all 4 groups using the χ2 test.
↵c Group differences in age and disease duration were compared using 1-way ANOVA.
↵d Group differences in MoCA and UPDRS-III were compared among all 4 groups using ANCOVA with adjustments for age and sex.
↵e Group differences in MoCA and UPDRS-III were compared among the 3 patient groups, using ANCOVA with adjustments for age and sex.